Maybe so. I too had hoped NWBO would buy their own CI. It would certainly better fit their style.
But for whatever reason... it appears to me to not be the plan. It appears to me that the plan is partnering three Direct trials with three BP's and their three CI's.
One thing that would be appealing to BP in that scenario is the completion of automated mfg for Direct. It is cheaper than L to begin with, then they added automated mfg. Of course... BP would probably want to see some efficacy first with Direct alone. Not sure if they would be persuaded by the previously published data or not. Sounds like you are not. Hopefully there is some further data. Maybe some of those early progressors ended up living much longer than historical norms, but admittedly might be hard to tell in such a shotgun with so few patients in each leg.
Imo there are 2 most important things for nwbo to accomplish asap. 1. get at least one flavor of therapy approved whether alone or in any combination for GBM or any other cancer 2. get enough credibility to attract serious money into the stock which will be enough to at least partially blow away the shorts and get the stock price to where it doesn't cost giving away so much of the store to raise money to keep going and keep moving forward.
News 
Market Data 
Discover 
